Related Experiment Video
Updated: Feb 24, 2026
06:47
A GMP-Compliant Procedure for the Generation of Gene-Modified T cells
Published on: October 6, 2023
1.1K
High Efficiency Low Cost Fibroblast Nucleofection for GMP Compatible Cell-based Gene Therapy.
Ziyang Zhang1,2,3, Alex Slobodianski2,4,3, Astrid Arnold3
1Department of Orthopedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
International Journal of Medical Sciences
|August 22, 2017
Summary
Optimizing non-viral DNA delivery for cell therapy, this study enhanced nucleofection efficiency in dermal fibroblasts. Modified protocols using specific media and solutions improved transfection rates for both rat and human cells.
Area of Science:
- Cell Biology
- Biotechnology
Background:
- Dermal fibroblasts are crucial for ex vivo DNA delivery in cell therapy and tissue engineering.
- Genetic modification of fibroblasts enables diverse adaptations for clinical gene therapy.
Purpose of the Study:
- Compare non-viral transfection methods for rat and human primary dermal fibroblasts.
- Optimize nucleofection protocols to maximize transfection efficiency.
Main Methods:
- Evaluated several non-viral transfection techniques, focusing on nucleofection.
- Modified existing nucleofection protocols for primary mammalian fibroblasts.
- Assessed transfection efficiency via flow cytometry measuring green fluorescent protein (GFP) expression.
Main Results:
- Dulbecco's Modified Eagle Medium (DMEM) with 10% Fetal Calf Serum (FCS) showed optimal transfection for rat dermal fibroblasts.
- Insulin, transferrin, and sodium selenite solution (ITS) demonstrated comparable efficiency to standard solutions for human dermal fibroblasts.
Conclusions:
- The modified nucleofection method shows potential for GMP-compatible therapeutic translational research.
- Optimized protocols enhance the utility of dermal fibroblasts in gene therapy applications.
